

FIGURE S1. Directed acyclic graph (DAG) illustrating potential mediators of changes in bone turnover markers (BTMs) with lifestyle intervention (1-14).




FIGURE S2. Flow of participants through the study

A detailed flow-chart as well as data on adherence to the intervention was published previously (15).

References

1. Hygum K, Starup-Linde J, Harslof T, Vestergaard P, Langdahl BL. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. *Eur J Endocrinol.* 2017;176(3):R137-R57.
2. Balint E, Szabo P, Marshall CF, Sprague SM. Glucose-induced inhibition of in vitro bone mineralization. *Bone.* 2001;28(1):21-8.
3. Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castano-Betancourt MC, Estrada K, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. *Diabetes Care.* 2013;36(6):1619-28.
4. Tonks KT, White CP, Center JR, Samocha-Bonet D, Greenfield JR. Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity. *The Journal of clinical endocrinology and metabolism.* 2017;102(4):1112-21.
5. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell.* 2000;100(2):197-207.
6. Eleftheriadis T, Kartsios C, Antoniadis G, Kazila P, Dimitriadou M, Sotiriadou E, et al. The impact of chronic inflammation on bone turnover in hemodialysis patients. *Ren Fail.* 2008;30(4):431-7.
7. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. *Biochem Biophys Res Commun.* 2005;331(2):520-6.
8. Carstensen M, Herder C, Kivimaki M, Jokela M, Roden M, Shipley MJ, et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. *Diabetes.* 2010;59(5):1222-7.
9. Koh JM, Khang YH, Jung CH, Bae S, Kim DJ, Chung YE, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. *Osteoporos Int.* 2005;16(10):1263-71.
10. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. *Nature.* 1999;402(6759):304-9.
11. Khosla S, Peterson JM, Egan K, Jones JD, Riggs BL. Circulating cytokine levels in osteoporotic and normal women. *The Journal of clinical endocrinology and metabolism.* 1994;79(3):707-11.
12. Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF. Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. *J Bone Miner Res.* 2000;15(3):402-14.
13. Shah K, Armamento-Villareal R, Parimi N, Chode S, Sinacore DR, Hilton TN, et al. Exercise training in obese older adults prevents increase in bone turnover and attenuates decrease in hip bone mineral density induced by weight loss despite decline in bone-active hormones. *J Bone Miner Res.* 2011;26(12):2851-9.
14. Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, et al. Weight loss, exercise, or both and physical function in obese older adults. *N Engl J Med.* 2011;364(13):1218-29.
15. Johansen MY, MacDonald CS, Hansen KB, Karstoft K, Christensen R, Pedersen M, et al. Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. *JAMA.* 2017;318(7):637-46.